Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with
advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced …

… We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs:
bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 …

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers,
raising hopes for many patients with otherwise unresponsive tumours. While these agents …

… cells including cells with tyrosine kinase inhibitor-resistant BCR-ABL1 kinase mutations. Our
… with tyrosine kinases inhibitors provides more efficient and selective inhibition of leukemia …

… of rare and complex mutations, and the efficacy of EGFR tyrosine kinase inhibitors (TKIs). …
receptor (EGFR) gene mutation responds well to EGFR tyrosine kinase inhibitors (TKIs) [1, 2]. …

… stem cell transplantation or receive third-line therapy with a different tyrosine kinase inhibitor
(TKI). It has been shown that the efficacy of third line dasatinib or nilotinib is limited, 7 so it is …

… In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral
doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with …

… tyrosine kinase inhibitors (TKI). In clinical practice, there are five TKI (imatinib, nilotinib,
dasatinib, bosutinib, and ponatinib) that are available in different scenarios and have distinct …

… Neratinib, at the time HKI 272, showed efficacy in suppressing EGFR … inhibitor of EGFR
and HER2. Afatinib (BIBW2992) is an orally available small molecule tyrosine kinase inhibitor …

… tyrosine kinase (Syk, ie, HMPL-523, fostamatinib) and Bruton tyrosine kinase (BTK) inhibitor
(… In this review, we will assess the safety and efficacy of tyrosine kinase inhibitors (TKIs) in …